The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

Neurizon (ASX:NUZ) has officially snagged a U.S. patent for its neurodegenerative disease and cancer drug candidate NUZ-001, ...

AI startup OpenAI has filed a patent in the United States, indicating that the company is exploring the development of an ...

Two new composition of matter patents granted in the US and Europe <li /> Patents provide protection relating to lead compound S-pindol ...

Neurizon Therapeutics has achieved a key milestone with a patent granted in the US for its lead drug candidate NUZ-001 to ...

MicroStrategy is changing its name to reflect its transformation from strictly a software firm to the self-described "world's ...

The Federal Circuit recently addressed a deceptively straightforward question: does a published U.S. patent application ...

The team filed trademark applications for the final six names — Utah Blizzard, Utah Mammoth, Utah Outlaws, Utah Hockey Club, ...

The U.S. has eviscerated the patent rights that help to power the innovation engine that drove its past technological and economic revolutions. Economic and historical evidence demonstrates that ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

On January 14, 2025, the United States Court of Appeals for the Federal Circuit issued a precedential decision in Lynk Labs, ...